Aardvark Therapeutics Statistics
Total Valuation
AARD has a market cap or net worth of $109.86 million. The enterprise value is $36.67 million.
| Market Cap | 109.86M |
| Enterprise Value | 36.67M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AARD has 21.88 million shares outstanding. The number of shares has increased by 102.94% in one year.
| Current Share Class | 21.88M |
| Shares Outstanding | 21.88M |
| Shares Change (YoY) | +102.94% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 15.94% |
| Owned by Institutions (%) | 19.39% |
| Float | 11.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.62 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.63, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.63 |
| Quick Ratio | 11.57 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.02% and return on invested capital (ROIC) is -43.39%.
| Return on Equity (ROE) | -66.02% |
| Return on Assets (ROA) | -40.38% |
| Return on Invested Capital (ROIC) | -43.39% |
| Return on Capital Employed (ROCE) | -98.51% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.50M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.56% |
| 50-Day Moving Average | 6.27 |
| 200-Day Moving Average | 7.83 |
| Relative Strength Index (RSI) | 40.37 |
| Average Volume (20 Days) | 142,934 |
Short Selling Information
The latest short interest is 509,891, so 2.33% of the outstanding shares have been sold short.
| Short Interest | 509,891 |
| Short Previous Month | 611,764 |
| Short % of Shares Out | 2.33% |
| Short % of Float | 4.63% |
| Short Ratio (days to cover) | 4.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -73.96M |
| Pretax Income | -69.89M |
| Net Income | -69.89M |
| EBITDA | -73.91M |
| EBIT | -73.96M |
| Earnings Per Share (EPS) | -$3.20 |
Balance Sheet
The company has $73.87 million in cash and $677,000 in debt, with a net cash position of $73.19 million or $3.34 per share.
| Cash & Cash Equivalents | 73.87M |
| Total Debt | 677,000 |
| Net Cash | 73.19M |
| Net Cash Per Share | $3.34 |
| Equity (Book Value) | 74.80M |
| Book Value Per Share | 3.42 |
| Working Capital | 74.27M |
Cash Flow
In the last 12 months, operating cash flow was -$69.41 million and capital expenditures -$4,000, giving a free cash flow of -$69.41 million.
| Operating Cash Flow | -69.41M |
| Capital Expenditures | -4,000 |
| Depreciation & Amortization | 42,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -69.41M |
| FCF Per Share | -$3.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AARD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.94% |
| Shareholder Yield | -102.94% |
| Earnings Yield | -60.25% |
| FCF Yield | -59.84% |
Analyst Forecast
The average price target for AARD is $11.11, which is 121.32% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.11 |
| Price Target Difference | 121.32% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |